Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2016 October;68(5) > Minerva Ginecologica 2016 October;68(5):557-65

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GINECOLOGICA

A Journal on Obstetrics and Gynecology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  HEREDITARY GENITAL AND BREAST CANCER


Minerva Ginecologica 2016 October;68(5):557-65

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Breast cancer in BRCA mutation carriers: medical treatment

Andrea MILANI 1, Elena GEUNA 1, Giorgia ZUCCHINI 1, Caterina AVERSA 2, Rossella MARTINELLO 2, Filippo MONTEMURRO 1

1 Investigative Clinical Oncology (INCO), Fondazione del Piemonte per l’Oncologia, Candiolo Cancer Institute (IRCCS), Turin, Italy; 2 University of Turin Medical School, Turin, Italy


PDF  


About 10% of breast cancers are associated with the inheritance of autosomal dominant breast cancer susceptibility alleles BRCA1 and BRCA2. Until recently, the medical management of BRCA mutation-associated breast cancer has not differed from that of the sporadic breast cancer counterpart. However, there is mounting evidence that this molecular alteration confers sensitivity or resistance to systemic therapies that can be exploited in terms of medical management. For example, studies support the use of platinum salts chemotherapy in BRCA mutated cancers. Moreover, a number of targeted therapies are showing activity in BRCA mutation carriers. Above all, BRCA defective tumor cells are particularly sensitive to Poly(ADP-ribose) polymerase (PARP) inhibitors. This review will summarize the state of the art of the medical treatment of breast cancer in BRCA mutation carriers, with a particular focus on chemotherapies and targeted therapies.

top of page

Publication History

Cite this article as

Corresponding author e-mail

filippo.montemurro@ircc.it